Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.

@article{Anderson2017ClinicopathologicalFA,
  title={Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.},
  author={Mary Ann Romer Anderson and Constantine Si Lun Tam and Thomas Eliot Lew and Surender K Juneja and Manu Juneja and David A Westerman and Meaghan Wall and Stephen Lade and Alexandra Gorelik and David C S Huang and John F Seymour and Andrew W Roberts},
  journal={Blood},
  year={2017},
  volume={129 25},
  pages={
          3362-3370
        }
}
The BCL2 inhibitor venetoclax achieves responses in ∼79% of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (RR-CLL/SLL), irrespective of risk factors associated with poor response to chemoimmunotherapy. A limitation of this targeted therapy is progressive disease (PD) in some patients. To define the risk factors for progression, the clinicopathological features of PD, and the outcomes for patients after venetoclax failure, we analyzed 67 heavily… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Similar Papers

Loading similar papers…